781 results about "Insulin" patented technology

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

The invention discloses a portable wound surface protection brace and an application method thereof, and belongs to the technical field of medical instruments. The brace is of a cylindrical structure, is made of EVA materials, has flexibility, non-toxic characteristics and good supporting performance and is externally wrapped with cotton cloth and provided with ventilation through holes, high-density cotton strips are fixed to the two ends of the inner wall to form a hollow structure, and the circumference of the outer wall can be adjusted through at least three sets of bandages with hook-and-loop fasteners. And an antibacterial coating is added, so that clinical application is expanded. During application, a wound surface is subjected to liquid extraction and hydrogen peroxide cleaning in the earlier stage and then covered with insulin mixed normal saline gauze, and the dressing is prevented from making contact with clothes in cooperation with a brace; and smearing mupirocin ointment in the later stage and performing infrared irradiation, and continuously using the brace to keep the wound dry and zero contact. The brace can be repeatedly used, can adapt to various wound types and patient body types, effectively solves the problems of wound adhesion and friction in traditional nursing, creates a high-oxygen healing environment, remarkably shortens wound healing time, relieves pain of patients and improves life quality, and has good clinical application and popularization value.

The invention discloses a culture medium and application thereof, and a method for in-vitro separation culture and adipogenic differentiation of precursor adipocytes in goat muscle, and relates to the technical field of cell culture, the culture medium comprises the following components: 8-12 [mu] g / mL of insulin, 8-12% by volume of fetal calf serum, 95-105 U / mL of penicillin, 95-105 [mu] g / mL of streptomycin and the like. On the basis of the prior art, a proper amount of liquiritin and pilocarpine are mainly added into a culture medium, and synergistic cooperation of the liquiritin and pilocarpine is found, so that the adipogenic differentiation capacity of cells such as mesenchymal stem cells and precursor adipocytes is remarkably improved, and the application range is wide. On the basis, the invention also provides a complete set of perfect in-vitro isolated culture and adipogenic differentiation method of the goat intramuscular precursor adipocytes, and a method and a way are provided for a series of researches developed through the goat primary intramuscular precursor adipocytes in the future.

The invention provides a tissue protection solution and application thereof. The tissue protection liquid comprises a basic culture medium; vitamins, wherein the vitamins comprise vitamin E; the antioxidant is prepared from at least one of N-acetylcysteine amide, superoxide dismutase and catalase; and a specific cell factor, wherein the specific cell factor comprises at least one of a ROCK inhibitor Y27632 and insulin. Therefore, when the tissue protection liquid is used for storing and transporting a tissue sample, the loss in the process from tissue sample separation to experiment starting can be reduced, the function and activity of tissue cells are ensured, and the success rate of establishment of various primary tissue cultures is effectively improved.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.

Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.

A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

Medication delivery methods, devices and systems are provided, the medication delivery device includes user interface elements, control circuitry, and a memory. The method includes receiving analyte measurement data of a user, presenting information related to the analyte measurement data to the user, and determining an intended dose of medication based on at least one of the analyte measurement data, optionally, therapeutic relevant conditions, therapy parameters, or a calculated insulin-on-board (IOB) value. When the user is queried to indicate that the user is ready for the delivery without presenting the intended dose on any of the one or more user interface elements of the medication delivery device, the intended dose is automatically delivered after receiving the user's indication.

The invention relates to the technical field of biological medicine, and provides a self-assembly polypeptide with an IGF-1 function and hair growth application thereof, and the self-assembly polypeptide comprises an end-capping group, a self-assembly unit and an insulin-like growth factor C structural domain polypeptide IGF-1C which are connected in sequence. The self-assembled polypeptide with the IGF-1 function, provided by the invention, has a beta-folded secondary structure, and can simulate a binding mode of IGF-1 and an insulin-like growth factor receptor IGF-1R and induce conformational change of an IGF-1R dimer, so that phosphorylation of the IGF-1R is promoted, physiological functions of the IGF-1R are simulated, and growth of hair is promoted. The self-assembled polypeptide with the insulin-like growth factor 1 (IGF-1) function, provided by the invention, can be applied to an alopecia area in a skin smearing manner, and particularly shows an excellent hair growth promoting effect in a mouse physiological alopecia model and an androgenic alopecia model.

The invention relates to the technical field of insulin pumps, in particular to a simple needle assisting module for an insulin pump, which comprises a bottom shell, and a fluid pushing module, a percutaneous insertion module and a reciprocating driving module which are arranged in the bottom shell, a mounting groove is formed in the bottom shell, the reciprocating driving module comprises a torsion spring, a guide block and a driving block, and the torsion spring has pre-torsion amount; one end of the torsion spring extends outwards and forms a connecting arm, a first limiting groove and a second limiting groove are formed in the installation groove, a strip-shaped groove is formed in the guide block, the driving block comprises a first sliding block used for fixing a needle body and a second sliding block used for fixing a sleeve, the guide block is arranged above the torsion spring, and the connecting arm of the torsion spring is movably arranged in the strip-shaped groove of the guide block. And in the process that the torsional spring releases the pre-torsion amount, the connecting arm drives the guide block to move in the mounting groove in the insertion or retraction direction. The insulin pump achieves needle assisting operation through cooperation of the extension arm at the end of the torsional spring and the guide block, and is simple in structure, convenient to install, good in stability and low in cost.

The present invention belongs to the technical field of plant extracts, and more specifically, relates to the use of a carob extract in a drug for improving glucose metabolism / polycystic ovary syndrome in women. The present invention discloses a pharmaceutical composition for improving glucose metabolism and treating polycystic ovary syndrome in women, the pharmaceutical composition comprising: carob extract, baicalein, cedrol, a bioactive peptide, a biopolysaccharide, and excipients. The composition of the present invention has the effects of lowering blood sugar and blood lipids, improving insulin function, and also has antioxidant and immunity-enhancing effects. By combining the above substances, a synergistic effect is achieved, further enhancing the effect of improving / treating polycystic ovary syndrome in women associated with abnormal glucose metabolism.

Safe insulin needle assembly includes protection sheath, needle, safety protection sleeve, pressure seat and needle holder. The needle is arranged on the central axis of the needle holder. The pressure seat is sheathed over the upper portion of the needle holder. The safety protection sleeve is sheathed on the needle holder and the pressure seat as a whole. The upper protection of the safety protection sleeve is connected to and cooperates with the pressure seat. The needle protrudes out of the top end of the upper portion of the safety protection sleeve. The lower portion of the safety protection sleeve is connected to and cooperates with the lower portion of the needle holder. The protection sheath is sheathed on the safety protection sleeve and the needle as a whole. The lower portion of the protection sheath is connected to and cooperates with the lower portion of the safety protection sleeve.

Provided are a new acylated insulin, a pharmaceutical preparation thereof, a pharmaceutical composition thereof containing a long-acting GLP-1 compound, and the medical use of the acylated insulin, the pharmaceutical preparation and the pharmaceutical composition.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention belongs to the technical field of cell biology, and particularly discloses a culture medium and a culture method of fish primary liver cells. The culture medium of the fish primary liver cells comprises the following components: 90% of an M199 culture medium, 10% of fetal calf serum, 100 U / mL of penicillin, 0.1 mg / mL of streptomycin, 5 ng / mL of EGF, 10 [mu] U / ml of insulin and 10 mM of dexamethasone. Based on the culture medium, an efficient and stable fish liver cell culture method is developed by combining a standardized anesthesia and disinfection process, a precise dissection and liver sampling method, an optimized tissue digestion and cell separation scheme, an efficient cell purification and adherent culture system, a stable passage technology and the like; a standardized hepatocyte line establishment operation process is defined, and the problems that species binding exists in an existing fish liver cell culture method, and a standardized culture process suitable for multiple fish fingerlings is difficult to form are solved.

The invention discloses a pharmaceutical composition for delaying oocyte senescence and application thereof, and relates to the technical field of biological medicine, and the pharmaceutical composition comprises alpha-ketoglutaric acid, a bicarbonate buffer solution, an energy metabolism substrate, polyvinyl alcohol, hormone, a growth factor and insulin-transferrin-selenium. The pharmaceutical composition for delaying oocyte aging disclosed by the invention is beneficial to improving the maturation rate of oocytes, reducing the cytoplasm fragmentation rate and the cleavage fragmentation rate, and improving the cleavage rate and the blastocyst rate; according to the invention, the content of beta-galactosidase is reduced, the function of mitochondria in the aging process after ovulation of the mature oocyte is improved, the membrane potential of the mitochondria in the aging process after ovulation of the mature oocyte is stabilized, the activity of the mitochondria is improved, and the normalization of RNA methylation modification in the aging process after ovulation of the mature oocyte is promoted.

Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution / high accuracy mass spectrometric techniques.

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.

The invention relates to the technical field of clinical test data acquisition and intelligent quality control, in particular to a clinical test data real-time acquisition and quality control management platform, which is characterized in that an operation starting time recording unit acquires a subject disinfection operation starting timestamp, an operation sequence delay calculation unit calculates actual operation delay based on standard consumed time, and a quality control unit calculates the actual operation delay based on the standard consumed time. The transmission delay processing unit separates transmission and operation delay through double timestamps, the actual collection time determining unit subtracts pure transmission delay time data and operation delay time data from the timestamps uploaded by the device through a reverse time restoration algorithm to obtain actual blood collection completion time, and the time window dynamic judging unit judges whether the time window dynamic judging unit is in real blood collection completion time or not through a dynamic offset boundary. The real time is compared with a preset time window to judge qualification, the physiological index correction unit corrects blood glucose and insulin values in real time through a layered framework and a correction rule base, and the dynamic association logic verification unit adjusts association rules and verifies index logic in combination with a three-dimensional decision matrix, so that support is provided for clinical tests.

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

Disclosed is an acylated insulin, a pharmaceutical formulation thereof, a pharmaceutical composition thereof with a long-acting GLP-1 compound, and a medical use of the acylated insulin, the pharmaceutical formulation and the pharmaceutical composition. Compared with insulin degludec or other insulin derivatives, the acylated insulin has an unexpected, significantly increased drug effect, a longer duration of action, a longer in vivo half-life, an excellent bioavailability, as well as better physical and chemical stabilities.

1. Name of the design product: storage bag. 2. Use of the design product: The design product is used for storing blood glucose meters, insulin and other items needed by diabetes patients. 3. Design points of the design product: in shape. 4. Picture or photo best indicating the design points: perspective view.

The invention relates to the technical field of medical instruments, and discloses a small insulin pump with an insulin depletion reminding function, which comprises a shell, a medicine storage tube is inserted into a bottom cavity of the shell, a piston I is inserted into one end of the medicine storage tube, a push rod I is inserted into one end of the piston I, and a motor is mounted at the top of the cavity. A motor is arranged in the shell, a lead screw is connected to the output end of the motor, a vibration ringing mechanism is arranged on the top of the motor, and a battery bin is arranged on the top in the shell. By arranging the vibration ringing mechanism, a daytime pure vibration insulin depletion reminding mode and a night sound vibration composite insulin depletion reminding mode can be flexibly switched according to use scenes; in addition, the reminding intensity is dynamically changed along with the stock of the liquid medicine, and a progressive reminding mechanism with an extremely strong warning effect is achieved.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

1. The name of the design product: insulin needle dismounting device (sharps box). 2. The use of the design product: used for dismounting insulin needle on sharps box. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and / or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and / or artificial pancreas (AP) algorithms, for example.